このページの翻訳は実験的なもので、現在開発中です。お待ちしております

NovoCure 将来の成長

Future 基準チェック /16

NovoCureの収益は年間5%で減少すると予測されていますが、年間収益は年間7.1%で増加すると予想されています。EPS は年間1.8%で減少すると予想されています。

主要情報

-5.0%

収益成長率

-1.8%

EPS成長率

Medical Equipment 収益成長	0%
収益成長率	7.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	28 Nov 2023

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

BMV:NVCR N - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	568	-264	N/A	N/A	6
12/31/2024	536	-226	-143	-149	7
12/31/2023	505	-217	-119	-91	7
9/30/2023	504	-197	-89	-62	N/A
6/30/2023	508	-174	-46	-21	N/A
3/31/2023	522	-141	-5	18	N/A
12/31/2022	538	-93	9	31	N/A
9/30/2022	543	-82	20	49	N/A
6/30/2022	545	-68	24	51	N/A
3/31/2022	538	-59	36	61	N/A
12/31/2021	535	-58	59	83	N/A
9/30/2021	546	-27	106	122	N/A
6/30/2021	545	-5	113	128	N/A
3/31/2021	527	12	99	115	N/A
12/31/2020	494	20	84	99	N/A
9/30/2020	450	19	40	53	N/A
6/30/2020	409	12	24	37	N/A
3/31/2020	380	9	22	33	N/A
12/31/2019	351	-7	16	27	N/A
9/30/2019	322	-27	27	36	N/A
6/30/2019	294	-41	19	27	N/A
3/31/2019	269	-55	4	11	N/A
12/31/2018	248	-64	-9	-2	N/A
9/30/2018	232	-59	-28	-22	N/A
6/30/2018	217	-59	-32	-25	N/A
3/31/2018	194	-64	-30	-23	N/A
12/31/2017	177	-62	-40	-33	N/A
9/30/2017	154	-73	-53	-44	N/A
6/30/2017	125	-95	N/A	-80	N/A
3/31/2017	105	-114	N/A	-104	N/A
12/31/2016	83	-132	N/A	-108	N/A
9/30/2016	65	-143	N/A	-120	N/A
6/30/2016	52	-135	N/A	-109	N/A
3/31/2016	41	-124	N/A	-102	N/A
12/31/2015	33	-112	N/A	-100	N/A
9/30/2015	25	-102	N/A	-91	N/A
6/30/2015	20	-94	N/A	-87	N/A
3/31/2015	18	-86	N/A	-83	N/A
12/31/2014	15	-81	N/A	-74	N/A
12/31/2013	10	-77	N/A	-53	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NVCR N今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NVCR N今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: NVCR N今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NVCR Nの収益 ( 7.1% ) MX市場 ( 7% ) よりも速いペースで成長すると予測されています。

高い収益成長: NVCR Nの収益 ( 7.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NVCR Nの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

NovoCure 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Recent updates

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘